Betamethasone Acetate
FDA-approved product (injectable, injection).
- Registered studies
- 27
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Airway obstruction
- Anemia
- Asthma
- Dermatitis
- Eye inflammation
- Hemorrhoid
- Nasal congestion
- Nephrotic syndrome
- Type III hypersensitivity reaction disease
- Ulcerative colitis
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Corticosteroids acting locally; Corticosteroids; Corticosteroids, potent (group iii); Corticosteroids, potent, other combinations; Glucocorticoids
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA55.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli34.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae29.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis26.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
27registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Betamethasone Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Nafarelin AcetateExisting use: Endometriosis58.6% AI-predicted activityagainst E. coli12 registered studies
- Goserelin AcetateExisting use: Breast cancer, Breast carcinoma, Carcinoma and 1 more58.5% AI-predicted activityagainst E. coli50+ registered studies
- Doxazosin MesylateExisting use: Benign prostatic hyperplasia, Hypertension, Myocardial infarction58.3% AI-predicted activityagainst E. coli50+ registered studies
- Chlorhexidine GluconateExisting use: Eye infection, Gingivitis, Infection and 2 more58.1% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- Zavegepant HydrochlorideExisting use: Migraine disorder57.8% AI-predicted activityagainst E. coliNo documented evidence found
- Bremelanotide AcetateExisting use: Mental or behavioural disorder, Physiological sexual disorder, Sexual dysfunction57.4% AI-predicted activityagainst E. coli1 registered study
- Trametinib Dimethyl SulfoxideExisting use: Cancer, Cutaneous melanoma, Glioblastoma multiforme and 5 more57.2% AI-predicted activityagainst E. coli16 registered studies
- Degarelix AcetateExisting use: Prostate adenocarcinoma, Prostate cancer, Prostate carcinoma57.2% AI-predicted activityagainst E. coli50+ registered studies
- Cisapride MonohydrateExisting use: Gastrointestinal disease56.3% AI-predicted activityagainst E. coli5 registered studies
- Prazosin HydrochlorideExisting use: Diabetes mellitus, Hypertension56.3% AI-predicted activityagainst E. coli50+ registered studies
- PemigatinibExisting use: Cancer, Cholangiocarcinoma, Neoplasm56.0% AI-predicted activityagainst E. coli50+ registered studies
- AtogepantExisting use: Migraine disorder56.0% AI-predicted activityagainst E. coli36 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
India Dexamethasone and Betamethasone
NCT03668860 · start 2018-09-20
Registered record
- Registry ID
- NCT03668860
- Conditions
- Preterm Birth; Antenatal Corticosteroids
- Interventions
- Dexamethasone 4 mg/ml; Betamethasone 4 mg/ml; Celestone Soluspan 6Mg/Ml Suspension for Injection; Dexamethasone Oral Tablet; Betamethasone Oral Tablet
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2018-09-20
- Completion
- 2019-12-31
- Enrolment
- 48
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPreterm Birth; Antenatal CorticosteroidsInterventionDexamethasone 4 mg/ml; Betamethasone 4 mg/ml; Celestone Soluspan 6Mg/Ml Suspension for Injection; Dexamethasone Oral Tablet +1 morePhasePhase 1Registry statusCompletedTreatment of FUS-Related ALS With Betamethasone - The TRANSLATE Study
NCT03707795 · start 2017-08-21
Registered record
- Registry ID
- NCT03707795
- Conditions
- Familial Amyotrophic Lateral Sclerosis
- Interventions
- Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days
- Study type
- INTERVENTIONAL
- Phase
- Early phase 1
- Registry status
- Completed
- Start
- 2017-08-21
- Completion
- 2019-01-10
- Enrolment
- 6
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionFamilial Amyotrophic Lateral SclerosisInterventionBetamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four daysPhaseEarly phase 1Registry statusCompletedA Comparative Effectiveness Randomised Placebo Controlled Pilot Trial of the Management of Acute Lumbar Radicular Pain
NCT03240783 · start 2017-07-08
Registered record
- Registry ID
- NCT03240783
- Conditions
- Acute Sciatica
- Interventions
- Betamethasone OR Dexamethasone Injectable; Normal Saline Flush, 0.9% Injectable Solution; Dexamethasone Oral Tablet; Sham Injection and/or oral placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Unknown
- Start
- 2017-07-08
- Completion
- 2018-10
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute SciaticaInterventionBetamethasone OR Dexamethasone Injectable; Normal Saline Flush, 0.9% Injectable Solution; Dexamethasone Oral Tablet; Sham Injection and/or oral placeboPhasePhase 2Registry statusUnknownSteroids in the Postoperative Transient Hypoparathyroidism Total Thyroidectomy
NCT02652884 · start 2016-01
Registered record
- Registry ID
- NCT02652884
- Conditions
- Transient Hypoparathyroidism
- Interventions
- phosphate and betamethasone acetate, 2 mL.; saline 0.9% NaCl
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Unknown
- Start
- 2016-01
- Completion
- 2017-12
- Enrolment
- 110
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTransient HypoparathyroidismInterventionphosphate and betamethasone acetate, 2 mL.; saline 0.9% NaClPhasePhase 4Registry statusUnknownTherapeutic Effect of Botulinum Toxin A for the Treatment of Plantar Fasciitis.
NCT03054610 · start 2015-01
Registered record
- Registry ID
- NCT03054610
- Conditions
- Plantar Fascitis; Botulinum Toxins, Type A
- Interventions
- Betamethason Sodium Phosphate; Ropivacaine; Botulinum Toxins, Type A
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2015-01
- Completion
- 2020-04
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPlantar Fascitis; Botulinum Toxins, Type AInterventionBetamethason Sodium Phosphate; Ropivacaine; Botulinum Toxins, Type APhasePhase 1Registry statusCompletedIntra-articular Betamethasone and the Hypothalamic-pituitary-adrenal Axis
NCT01799408 · start 2012-10
Registered record
- Registry ID
- NCT01799408
- Conditions
- Adrenal Suppression
- Interventions
- Not recorded
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2012-10
- Completion
- 2013-02
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAdrenal SuppressionInterventionNot recordedPhaseNot recordedRegistry statusCompletedLumbar Epidural Steroid Injections for Spinal Stenosis Multicenter Randomized, Controlled Trial (LESS Trial)
NCT01238536 · start 2011-04
Registered record
- Registry ID
- NCT01238536
- Conditions
- Spinal Stenosis; Low Back Pain
- Interventions
- Epidural steroid with local anesthetic injection; Epidural local anesthetic injection; Epidural steroid injection; Epidural local anesthetic injection
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2011-04
- Completion
- 2015-09
- Enrolment
- 400
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSpinal Stenosis; Low Back PainInterventionEpidural steroid with local anesthetic injection; Epidural local anesthetic injection; Epidural steroid injection; Epidural local anesthetic injectionPhasePhase 4Registry statusCompletedAntenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
NCT01222247 · start 2010-10
Registered record
- Registry ID
- NCT01222247
- Conditions
- Pregnancy; Respiratory Distress Syndrome; Pregnancy Outcomes; Preterm Birth
- Interventions
- Betamethasone; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2010-10
- Completion
- 2022-08-31
- Enrolment
- 2,831
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPregnancy; Respiratory Distress Syndrome; Pregnancy Outcomes; Preterm BirthInterventionBetamethasone; PlaceboPhasePhase 3Registry statusCompletedEfficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in Cortisosensitive Dermatosis
NCT01011621 · start 2010-02
Registered record
- Registry ID
- NCT01011621
- Conditions
- Dermatitis, Atopic; Dermatitis, Contact; Dermatitis, Seborrheic; Psoriasis
- Interventions
- 0.5% prednisolone acetate cream; 0.1% betamethasone valerate cream
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Unknown
- Start
- 2010-02
- Completion
- Not recorded
- Enrolment
- 170
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDermatitis, Atopic; Dermatitis, Contact; Dermatitis, Seborrheic; PsoriasisIntervention0.5% prednisolone acetate cream; 0.1% betamethasone valerate creamPhasePhase 3Registry statusUnknownAntenatal Corticoid Therapy for Late Preterm Babies
NCT00675246 · start 2008-05
Registered record
- Registry ID
- NCT00675246
- Conditions
- Hyaline Membrane Disease; Transient Tachypnea
- Interventions
- Betamethasone
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2008-05
- Completion
- 2010-05
- Enrolment
- 320
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHyaline Membrane Disease; Transient TachypneaInterventionBetamethasonePhaseNot applicableRegistry statusCompletedProlotherapy Versus Steroids for Thumb Carpo-metacarpal Joint Arthritis
NCT00685880 · start 2008-05
Registered record
- Registry ID
- NCT00685880
- Conditions
- Thumb Carpometacarpal Joint Osteoarthritis
- Interventions
- Prolotherapy (10% dextrose solution); Betamethasone
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Terminated
- Start
- 2008-05
- Completion
- 2010-07
- Enrolment
- 2
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionThumb Carpometacarpal Joint OsteoarthritisInterventionProlotherapy (10% dextrose solution); BetamethasonePhaseNot applicableRegistry statusTerminatedORTHOVISC Shoulder Osteoarthritis Study
NCT00436969 · start 2006-12
Registered record
- Registry ID
- NCT00436969
- Conditions
- Glenohumeral Osteoarthritis
- Interventions
- Orthovisc; Control
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2006-12
- Completion
- 2011-08
- Enrolment
- 274
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGlenohumeral OsteoarthritisInterventionOrthovisc; ControlPhasePhase 3Registry statusCompleted